Boom Capital
VC Fund
San Francisco, United States
Boom Capital is a pre-seed fund for deeply technical, under-networked founders trying to build their companies. It was incorporated in 2017 and is based in San Francisco, California.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Boom Capital invests in
Stages Boom Capital invests in
Countries Boom Capital invests in
Round sizes
Round size
- Seed
- $2.8M–$10M
- Series A
- $25M–$52M
Investment Focus
Industry
- Biotechnology 6 (35%)
- Health Care 5 (29%)
- Medical 3 (18%)
- Artificial Intelligence 3 (18%)
- Hospital 2 (12%)
Stage
- Seed 9 (53%)
- Series A 2 (12%)
- Pre-Seed 1 (6%)
- Series B 1 (6%)
- Convertible Note 1 (6%)
Country
- United States 10 (59%)
- Singapore 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Harmonic Discovery
|
Harmonic Discovery operates as a pharmaceutical company that develops a platform that combines computing and experimentation. | $8M / Seed / Sep 08, 2022 | |
Monod Bio
|
Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington. | $25M / Seed / Aug 15, 2022 | |
Endpoint Health
|
Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-poweredpatient discovery platform, to identify and match high-potential therapies to the patients most likely to respond. | $52M / Series A / Jun 02, 2022 | |
Diligent Robotics
|
Diligent Robotics develops technically advanced robots with mobile manipulation, social intelligence, and human-guided learning capabilities to collaborate with and adapt to humans in everyday environments.Diligent Robotics' service robots are designed to participate and work together with teams of humans. The company's first product,Moxi, is a hospital robot assistant that helps clinical staff with logistical tasks, allowing them to have more time on direct patient care, improving patient satisfaction, quality of service, and safety. | $30M / Series B / Apr 11, 2022 | |
Treeswift
|
Treeswift utilizes robotic and machine learning technology to build forestry tools. | $4.8M / Seed / Mar 28, 2022 | |
Fauna Bio
|
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bioleverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases. | $9M / Seed / Sep 21, 2021 | |
Shiok Meats
|
Shiok Meats is cellular aquaculture and cell-based meat company. With a mission to bring clean and healthy meats and seafood by harvesting from cells instead of animals. Shiok Meats brings cell-based crustacean meats that are animal-, health- and environment-friendly.Shiok Meats was founded in 2018 and is headquartered in Central Region,Singapore. | Convertible Note / Jul 21, 2021 | |
|
Shiok Meats
|
Shiok Meats is cellular aquaculture and cell-based meat company. With a mission to bring clean and healthy meats and seafood by harvesting from cells instead of animals. Shiok Meats brings cell-based crustacean meats that are animal-, health- and environment-friendly.Shiok Meats was founded in 2018 and is headquartered in Central Region,Singapore. | $10M / Seed / Jul 21, 2021 | |
Orchid
|
Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes. Orchid results are developed withworld-class experts in reproductive medicine and genetics to give its clients the most accurate results.Orchid offers a “Couple Report” that utilizes an at-home saliva test to analyze each person’s genomes to detect the probability of genetic risks, then models how their DNA together will combine in a future child. If elevated risk is detected, Orchid provides insights to help couples monitor biomarkers, adapt their diet or elect for procedures, such as in vitro fertilization. It was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California. | $4.5M / Seed / Apr 07, 2021 | |
Synthesis AI
|
Synthesis AI is a data generation platform for computer vision. Synthesis AI is pioneering synthetic data technology to build more capable AI. | $4.5M / Seed / Apr 07, 2021 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boom Capital invest in?
Boom Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Boom Capital's check size?
Boom Capital typically joins rounds of $2.8M–$10M at Seed and $25M–$52M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boom Capital participates in.
When did Boom Capital last invest?
The most recent investment recorded for Boom Capital closed in Sep 2022. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
